Literature DB >> 25657192

Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.

Ewan K Cobran1, Ronald C Chen2, Robert Overman3, Anne-Marie Meyer4, Tzy-Mey Kuo5, Jonathon O'Brien4, Til Sturmer4, Nathan C Sheets2, Gregg H Goldin2, Dolly C Penn2, Paul A Godley2, William R Carpenter4.   

Abstract

Intensity-modulated radiation therapy (IMRT), an innovative treatment option for prostate cancer, has rapidly diffused over the past decade. To inform our understanding of racial disparities in prostate cancer treatment and outcomes, this study compared diffusion of IMRT in African American (AA) and Caucasian American (CA) prostate cancer patients during the early years of IMRT diffusion using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. A retrospective cohort of 947 AA and 10,028 CA patients diagnosed with localized prostate cancer from 2002 through 2006, who were treated with either IMRT or non-IMRT as primary treatment within 1 year of diagnoses was constructed. Logistic regression was used to examine potential differences in diffusion of IMRT in AA and CA patients, while adjusting for socioeconomic and clinical covariates. A significantly smaller proportion of AA compared with CA patients received IMRT for localized prostate cancer (45% vs. 53%, p < .0001). Racial differences were apparent in multivariable analysis though did not achieve statistical significance, as time and factors associated with race (socioeconomic, geographic, and tumor related factors) explained the preponderance of variance in use of IMRT. Further research examining improved access to innovative cancer treatment and technologies is essential to reducing racial disparities in cancer care.
© The Author(s) 2015.

Entities:  

Keywords:  Epidemiology and End Results (SEER)–Medicare; Surveillance; diffusion; intensity-modulated radiation therapy (IMRT); radiation therapy

Mesh:

Year:  2015        PMID: 25657192      PMCID: PMC4570865          DOI: 10.1177/1557988314568184

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  28 in total

1.  Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison.

Authors:  G O De Meerleer; L A Vakaet; W R De Gersem; C De Wagter; B De Naeyer; W De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

3.  Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States).

Authors:  Jacob H Cohen; Victor J Schoenbach; Jay S Kaufman; James A Talcott; Anna P Schenck; Sharon Peacock; Michael Symons; M Ahinee Amamoo; William R Carpenter; Paul A Godley
Journal:  Cancer Causes Control       Date:  2006-08       Impact factor: 2.506

4.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Authors:  Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.

Authors:  Kevin Forsythe; Seth Blacksburg; Nelson Stone; Richard G Stock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-16       Impact factor: 7.038

6.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

7.  Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.

Authors:  Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

8.  Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.

Authors:  Laurens Holmes; Wenyaw Chan; Zhidong Jiang; Doriel Ward; E James Essien; Xianglin L Du
Journal:  Cancer Control       Date:  2009-04       Impact factor: 3.302

9.  Differential receipt of sentinel lymph node biopsy within practice-based research networks.

Authors:  Anne-Marie Meyer; Katherine E Reeder-Hayes; Huan Liu; Stephanie B Wheeler; Dolly Penn; Bryan J Weiner; William R Carpenter
Journal:  Med Care       Date:  2013-09       Impact factor: 2.983

Review 10.  Intensity-modulated radiation therapy: supportive data for prostate cancer.

Authors:  Oren Cahlon; Margie Hunt; Michael J Zelefsky
Journal:  Semin Radiat Oncol       Date:  2008-01       Impact factor: 5.934

View more
  3 in total

1.  Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes.

Authors:  Paolo Goffredo; Timothy J Robinson; Linda M Youngwirth; Sanziana A Roman; Julie A Sosa
Journal:  Endocrine       Date:  2016-03-30       Impact factor: 3.633

2.  Worsening Racial Disparities in Utilization of Intensity Modulated Radiation Therapy.

Authors:  Ryan J Hutten; Chris R Weil; David K Gaffney; Kristine Kokeny; Shane Lloyd; Charles R Rogers; Gita Suneja
Journal:  Adv Radiat Oncol       Date:  2022-01-20

3.  Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.

Authors:  Christopher R Manz; Angela C Tramontano; Hajime Uno; Ravi B Parikh; Justin E Bekelman; Deborah Schrag
Journal:  JAMA Netw Open       Date:  2022-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.